For more information on any of the studies listed below, call (405) 271-7805 or email email@example.com.
ACTIVE SLE TRIALS
ACE Project Protocol # ALE06 An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable, Quiescent Systemic Lupus Erythematosus (SLE) Short Title: Randomized MMF Withdrawal in SLE (Currently Recruiting)
Bristol Myer Squibb IM101-345 Clarification of Abatacept Effects in SLE with Integrated Biologic and Clinical Approaches (The ABC Study) Investigator Initiated Trial (Currently Recruiting)
Bristol Myer Squibb IM128-027 A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects with Active Systemic Lupus Erythematosus- (Currently Recruiting)
EMD Serono, Inc. EMR700461-024 A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects with Systemic Lupus Erythematosus (SLE) who Completed Protocol EMR-700461-023 (Closed Recruitment)
GlaxoSmith Kline (GSK) Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the absence of confounding polypharmacy (The BLAST study). Investigator Initiated Trial (Currently Recruiting)
HUMAN GENOME SCIENCES (GSK) Protocol Number: HGS1006-C1124 A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA™ (belimumab) SABLE project (Currently recruiting) Non- Interventional
Lupus Clinical Trials Consortium (LCTC) A Prospective Registry to Study Presentation, Clinical Course, Treatment Patterns, and Outcomes in Patient with Systemic Lupus Erythematosus (Ongoing – Closed recruiting) Non-Interventional
THE SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS
Registry for Atherosclerosis, Neuropsychiatric Disorders and Cancer Risk in SLE (Ongoing-Closed recruiting) Non-Interventional.
ACTIVE RA TRIALS
PFIZER Inc. Protocol A3921024 A Long-Term, Open-Label Follow-up Study of Tasocitinib (CP-690,550) for Treatment of Rheumatoid (Ongoing – Closed Recruitment)
Pfizer Inc. Protocol Number A3921133 Phase 3B/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis (Currently Recruiting)
UCB BioSciences, Inc. Protocol Number UP0017 A Multicenter Postmarketing Study To Evaluate The Placental Transfer of Certolizumab Pegolin in Pregnant Women Receiving Treatment With CIMZIA® (CERTOLIZUMAB PEGOL) (Currently Recruiting)